Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
NCT05192122
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
Doctors conducted a small test to see if patients with a certain type of cancer called multiple myeloma who have undergone a stem cell transplant would still be at risk for the cancer to come back after they stop a certain kind of treatment. This test was only done on patients who had no signs of cancer left after the transplant.
Doctors conducted a small test to see if patients with a certain type of cancer called multiple myeloma who have undergone a stem cell transplant would still be at risk for the cancer to come back after they stop a certain kind of treatment. This test was only done on patients who had no signs of cancer left after the transplant.
Third Opinion AI Generated Synopsis
Trial Summary
A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.
A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
